The small-molecule formyl peptide receptor biased agonist, Compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices.

Vasodilation to Cmpd17b, but not standard-of-care vasodilators, is maintained under inflammatory conditions, with additional inhibition of PAH-relevant cytokine release. Our study provides the first evidence that targeting FPR, using a biased agonist, simultaneously targets vascular function and inflammation, supporting the development of FPR-based pharmacotherapy to treat PAH.